bioAffinity Technologies Files S-1

TL;DR

bioAffinity Tech S-1 filed: $1.18M rev YTD, $10.1M assets, $3.1M liab as of 9/30/24.

AI Summary

bioAffinity Technologies, Inc. filed an S-1 form on November 27, 2024, detailing its financial status. For the nine months ended September 30, 2024, the company reported revenue of $1.18 million. As of September 30, 2024, bioAffinity Technologies had total assets of $10.1 million and total liabilities of $3.1 million. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This S-1 filing provides a snapshot of bioAffinity Technologies' financial health and operational data, crucial for investors and stakeholders to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — The company's financial performance and the nature of S-1 filings, which often precede significant corporate events like IPOs or secondary offerings, suggest a medium risk level.

Key Numbers

• $1.18M — Revenue (YTD) (Revenue for the nine months ended September 30, 2024.)
• $10.1M — Total Assets (Total assets as of September 30, 2024.)
• $3.1M — Total Liabilities (Total liabilities as of September 30, 2024.)
• 2024-09-30 — Reporting Date (Key financial reporting date for assets and liabilities.)

Key Players & Entities

• bioAffinity Technologies, Inc. (company) — Filer of the S-1 form
• 20241127 (date) — Date of filing
• $1.18 million (dollar_amount) — Revenue for the nine months ended September 30, 2024
• $10.1 million (dollar_amount) — Total assets as of September 30, 2024
• $3.1 million (dollar_amount) — Total liabilities as of September 30, 2024
• Delaware (location) — State of incorporation

FAQ

Key Financial Figures

• $0.007 — 4,230 shares of common stock, par value $0.007 per share (the "Common Stock"), of bioA
• $1.20 — e of (i) our Common Stock on Nasdaq was $1.20 per share, and (ii) our Tradeable Warra
• $0.60 — i) our Tradeable Warrants on Nasdaq was $0.60 per Tradeable Warrant. There is no esta
• $1.235 billion — gross revenue is equal to or more than $1.235 billion; (iii) the date on which we have issued
• $1 billion — date on which we have issued more than $1 billion in nonconvertible debt during the previ
• $250 million — maller reporting company" until we have $250 million or more in public float (based on our C
• $700 m — on our Common Stock) that is less than $700 million, annual revenues of $100 million
• $100 million — s than $700 million, annual revenues of $100 million or more during the most recently comple

Filing Documents

• forms-1.htm (S-1) — 3620KB
• ex5-1.htm (EX-5.1) — 16KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 14KB
• forms-1_001.jpg (GRAPHIC) — 22KB
• ex5-1_001.jpg (GRAPHIC) — 2KB
• 0001493152-24-048047.txt ( ) — 12152KB
• biaf-20240930.xsd (EX-101.SCH) — 57KB
• biaf-20240930_cal.xml (EX-101.CAL) — 96KB
• biaf-20240930_def.xml (EX-101.DEF) — 261KB
• biaf-20240930_lab.xml (EX-101.LAB) — 479KB
• biaf-20240930_pre.xml (EX-101.PRE) — 392KB
• forms-1_htm.xml (XML) — 2292KB

RISK FACTORS

RISK FACTORS 6 THE OCTOBER OFFERINGS 30

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 33 SELLING STOCKHOLDERS 34 MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY 36

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS 37

BUSINESS

BUSINESS 45 MANAGEMENT 57 EXECUTIVE AND DIRECTOR COMPENSATION 60 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 64

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 66 PLAN OF DISTRIBUTION 69 EXPERTS 70 LEGAL MATTERS 70 WHERE YOU CAN FIND ADDITIONAL INFORMATION 70 INDEX TO FINANCIAL STATEMENTS F-1 The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the Common Stock offered under this prospectus. The registration statement, including the exhibits, can be read on our website and the website of the Securities and Exchange Commission. See "Where You Can Find Additional Information." Information contained in, and that can be accessed through our web site, www.bioaffinity.com, shall not be deemed to be part of this prospectus or incorporated herein by reference and should not be relied upon by any prospective investors for the purposes of determining whether to purchase the Common Stock offered hereunder. Unless the context otherwise requires, the terms ""we," "us," "our," "the Company," "bioAffinity" and "our business" refer to bioAffinity Technologies, Inc. and "this offering" refers to the offering contemplated in this prospectus. i ABOUT THIS PROSPECTUS Neither we nor the Selling Stockholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the Selling Stockholders take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of the date on the front cover of the prospectus. Our business, financial condition, results of operations and prospects may have changed since that da

View Full Filing

View this S-1 filing on SEC EDGAR